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356 A. Aiello et al.Diabetic foot (DF) is a chronic and highly disabling
complication of diabetes that affects patients with pe-
ripheral neuropathy (PN) and/or peripheral arterial disease
(PAD). It has been traditionally considered that DF is
caused by PN, but epidemiological data have shown that
the prevalence of PAD is high in diabetic patients [1,2] and,
associated or not with PN, can be found in 50% of cases
with lower limb lesions [3]. The presence of PN may mask
the typical clinical symptoms of PAD, such as claudication
and pain at rest, and so an ulcer that fails to heal and/or
more or less extensive gangrenous areas of the foot may be
the ﬁrst signs of previously unknown PAD.
DF generally affects patients with long duration of the
disease and, as they may also be affected by various co-
morbidities, they may be particularly fragile and difﬁcult to
manage clinically. The high rate of (especially cardiovascular)
co-morbidities means that attention should not be exclu-
sively focussed on the foot with an ulcer, but takes into ac-
count the patient as a whole and the various clinical
conditions that can jeopardise his or her life and have a
negative impact on treatment. It would be a mistake to
consider the foot separately fromthe restof thebodybecause
DF is a local manifestation of a systemic condition.
Another aspect that needs to be considered is the
complexity of the manifestations of DF, which include
ischaemia, neuropathy, biomechanical problems, infection,
wound healing and so on. This complexity practically rules
out any single specialist approach and requires the assis-
tance of a multidisciplinary team capable of guaranteeing
functional rehabilitation of the foot and, whenever
possible, optimising the patient’s clinical condition. The
team should include a diabetologist, a vascular surgeon, an
interventional radiologist, an orthopaedic surgeon, a
specialist in infectious diseases, a cardiologist, an ortho-
paedic technician and a podiatrist. A multidisciplinary
approach has proved to be the winning formula in many
published experiences [4,5].
The high prevalence of PAD in diabetic patients in
general [1e3,6,7] is due to the nature of the disease itself,
but other factors such as the longer average life span, a
longer disease duration and (in diabetics with end-stage
renal failure) the role of dialytic treatment should not be
underestimated [8]. This indicates the burden that the
complication may have for individual patients and society
as a whole, given its chronic nature and the relatively
frequent recourse to major lower limb amputations.
However, it is worth pointing out that, despite the pro-
gressive increase in the prevalence of PAD in diabetic pa-
tients, the number of major amputations has decreased
because of the growing use of distal revascularisation [9].
At this point, it is worth remembering that:
 there is a long tradition in the ﬁeld of distal revascu-
larisation in Italy, which is one of the few countries
where revascularisation is routinely used to treat dia-
betic patients [10e13];
 Italy has one of the lowest prevalence rates of major
amputations in Europe which is 3.1/100,000 inhabitants
[9]; and Eurodiale data (obtained from 14 European reference
centres) show that the participating Italian centres are
among the ﬁrst in terms of clinical outcome, with the
highest rate of wound healing and the lowest rates of
major amputations [3,14].
On the basis of these considerations, we believe it is
appropriate to produce a consensus document concerning
the treatment of PAD and limb salvage in diabetic patients
that is based on the Italian experience, to share with the
scientiﬁc community. In drawing up this document, we
have referred to the international literature published over
the past 20 years, especially the one produced by Italian
groups because of their increasingly greater use of endo-
vascular treatment and the large number of treated pa-
tients [10e13,15e17].Epidemiology and prevalence
The published prevalence rates of PAD vary widely be-
tween studies. A recent review by Jude indicates that its
prevalence among diabetics is 8e30% [18]; Faglia esti-
mates a prevalence of about 22% in patients with newly
diagnosed type 2 diabetes [2], and Prompers a prevalence
of about 50% in diabetic patients with foot ulcers [3].Characteristics of PAD in diabetic patients
PAD in diabetic subjects is a systemic, obstructive athero-
sclerotic disease with some particular histopathological
characteristics, especially the higher incidence of vascular
calciﬁcations [19e24]. In comparison with non-diabetics,
diabetic patients with PAD are generally younger, have a
higher body mass index (BMI), are more often neuropathic
and have more cardiovascular co-morbidities [25].
The clinical peculiarities of obstructive arteriopathy in
diabetic patients are its rapid progression and prevalently
distal and bilateral topographical expression. Furthermore,
the arterial walls are often calciﬁed and occlusions are
more frequent than stenoses. The natural adaptive
response to reduced ﬂow inside an artery is neo-
angiogenesis, but this and the capacity to generate
compensatory collateral circulations are reported to be
reduced in diabetic subjects [26e33], even if a recent
observation shows better collateral development towards
the culprit vessel at least in the coronary artery disease
[34].Anatomical characteristics
The anatomical distribution of PAD is different in the
diabetic and non-diabetic populations. In diabetic subjects,
PAD more frequently affects below-the-knee vessels such
as the tibial and peroneal arteries and is symmetric and
multi-segmental, and the collateral vessels can also be
affected by stenosis [35,36].
The severity of the lesions is also different in the two
populations, with diabetic subjects having a larger number
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peroneal, anterior and posterior tibial and even the plantar
arteries [37,38].
It is essential to deﬁne the type and extent of PAD when
deciding the clinical prognosis because infra-popliteal
involvement is associated with a high risk of major
amputation in diabetic subjects who have not undergone
distal revascularisation [39]:
 PAD is a common complication of diabetes and affects
more than 50% of the patients with ulcers.
 Its localisation is predominantly distal and symmetrical,
and it is rapidly progressive.Evolution and prognosis
The initial clinical picture is rarely symptomatic (claudi-
cation may be absent because of concomitant PN) and
more frequently characterised by the ischaemic lesions
and gangrene typical of more advanced disease stages. For
this reason, the current clinical classiﬁcations of PAD are
not really applicable in the presence of diabetes and foot
ulcers, and it is more appropriate to use the University of
Texas Wound Classiﬁcation System [40]. PAD is present in
50% of diabetic patients with ulcerative wounds and is a
widely recognised risk factor for major amputations.
The negative prognosis of ischaemic ulcerative lesions
in diabetic patients is probably related to the co-existence
of factors such as the anatomical distribution of PAD,
infection, neuropathy and renal insufﬁciency and the
concomitant presence of other coronary and cerebral
vascular manifestations. About 27% of diabetic subjects
with PAD experience progressive disease in the following 5
years, and 4% undergo major amputation; about 20%
manifest a cardiovascular event (myocardial infarction or
stroke). The prognosis of diabetic patients with critical
limb ischaemia (CLI) is even more serious as 30% may
require a major amputation and 20% die of cardiovascular
disease within 1 year [41].
Non-revascularisation of PAD diabetic patients is an
independent predictive factor of amputation [16] and also
an independent determinant of poor survival [18].
The risk of co-existing ischaemic heart disease in dia-
betic patients with PAD is 50% [42e44]. The simultaneous
presence of silent and non-silent myocardial ischaemia is
signiﬁcantly more frequent in diabetic than in non-
diabetic subjects [45,46], which means that all diabetic
patients with PAD should undergo diagnostic in-
vestigations of the coronary district in order to identify any
previously unknown coronary disease.
Diabetic patients with PAD have frequently a concom-
itant chronic renal insufﬁciency (CRI) requiring haemo-
dialysis, which means that the vascular damage is more
severe and progresses more rapidly than in diabetic pa-
tients without end-stage renal disease. Renal disease is
one of the most important factors underlying the unfav-
ourable course of an ulcerative lesion, and dialysis is one of
the main risk factors for ulceration and amputation in
diabetic patients [3,47].Distal revascularisation in dialysed patients is a chal-
lenge because they are more susceptible to infections,
uraemia further hinders the healing of ulcerative lesions
and PAD is complicated by the presence of marked calci-
ﬁcations of the vessel walls. Furthermore, the risk of major
amputation is 4.7 times higher than in non-dialysed sub-
jects [8].
Diabetic subjects with renal insufﬁciency also experi-
ence more perioperative complications such as sepsis and
heart failure, and there is a high rate of mortality due to
surgical revascularisation (2.4e13%) [8].
However, despite the complexity of the local and gen-
eral management of diabetic PAD patients undergoing
dialysis, recent data show that 1-year limb salvage can be
as high as 65e75%. [48]
 Diabetic patients rarely experience the early symp-
tomatic manifestation of PAD (claudication) because of
the frequent concomitance of sensitive motor
neuropathy.
 The current classiﬁcations of PAD in non-diabetic pa-
tients do not apply to diabetics.
 Ischaemic wounds, ulcers and gangrene are frequent
initial signs of PAD in diabetic patients.
 It is appropriate to use the University of Texas Wound
Classiﬁcation System.
 Fifty percent of diabetic patients with PAD also have
possibly silent ischaemic heart disease: a thorough
diagnosis is needed that also includes the coronary and
carotid regions.
 Diabetic patients with CLI undergoing dialysis have a
more serious and rapidly progressive form of PAD that
is very difﬁcult to treat.Assessing impaired perfusion in a DF
In the case of suspected PAD, a number of examinations
need to be carried in order to assess the severity of the
clinical picture. Centres that mainly screen and manage
less complex wounds should non-invasively determine
whether the patient is ischaemic or not and, above all,
evaluate whether the ischaemia has any negative effect on
the evolution of the ulcerative lesion.
It is important to emphasise the need to transfer
ischaemic patients to a specialised, multidisciplinary
centre as soon as possible [49]. Published data show that
ischaemic lesions are less likely to heal, and that the onset
of infection can transform an originally mild lesion into
gangrene. This risk increases with the duration of the
lesion and the continuation of ineffective treatment
without appropriate revascularisation.
PAD should be sought in all diabetic subjects with foot
ulcers. The evaluation begins with a search for arterial
pulses (femoral, popliteal, posterior tibial and dorsalis
pedis) but, despite this being essential in the case of
epidemiological investigations, it has some limitations
when it comes to verifying the presence of an ischaemic
component in patients affected by ongoing ulcers. In
particular, the dorsalis pedis pulse may be absent in up to
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ducible and may sometimes be detected even in the
presence of ischaemia. The posterior tibial pulse seems to
be more reliable and provides more certain information
concerning the presence or absence of ischaemic condi-
tion. It needs to be underlined that the obstruction of one
tibial artery (or only the plantar arch in diabetics) can lead
to an ischaemic ulcer, and so the presence of a single well-
palpated tibial pulse does not exclude it. However, the
greatest limitation of using pulses to evaluate ischaemia is
the fact that an absent pulse does not provide any infor-
mation concerning perfusion deﬁcit and therefore the
healing potential of the lesion itself [50]. In a large-scale
survey of diabetics with an ulcer and peripheral
ischaemia, Apelqvist found that >50% of the patients
would not have been classiﬁed as ischaemic if they had not
undergone an instrumental evaluation [51].
Furthermore, the semiotic methods that are widely
used when diagnosing non-diabetics, such as the search
for femoral pulse or position-related changes in foot
colour, can be inﬂuenced by many confounding factors and
so using them alone to diagnose PAD in diabetic subjects is
considered not sufﬁcient [52].
It is clear that the presence of an ulcer requires a more
objective evaluation, not least because this can guide
therapeutic decision-making, particularly the need for
revascularisation.
Diabetic patients with limb ischaemia can be non-
invasively evaluated in different ways but, as each of
them has different advantages, disadvantages and limita-
tions, it is often necessary to integrate them.
The ankle/brachial pressure index (ABI) is the ratio of the
systolic pressure in the ankle to that in the arm and is
considered a reference test insofar as it is reproducible,
sensitive and speciﬁc in detecting PAD. In diabetics, it
should be calculated using whichever is the lower of the
systolic pressure in the anterior and posterior tibial arteries
[53]. The American Diabetes Association recommends using
the ABI to screen all diabetics aged >50 years and all
insulin-dependent diabetics regardless of age in the pres-
ence of other cardiovascular risk factors. On the basis of the
ABI, it is possible to deﬁne the entity of peripheral vascular
impairment: 0.91e1.30 Z normality; 0.70e0.90 Z mild;
0.40e0.69 moderate; and <0.40 Z severe [54]. From the
clinical point of view, in the presence of an ulcer, an ABI of
>0.7 is indicative of reduced perfusion but it is still sufﬁ-
cient to ensure healing. In any case, a reduced ABI is an
important predictor of cardiovascular events and premature
death [55]. An ABI of >1.30 indicates that the arteries are
scarcely compressible because of the presence of extended
calciﬁcation of the walls, but does not exclude the presence
of PAD [56]. This value has negative prognostic implications
per se insofar as it correlates with PN [57] and is a risk factor
for cardiovascular events [58], but is non-diagnostic in the
case of PAD. The same calciﬁcations may sometimes lead to
a falsely normal ABI, but the search for pulses can help in
diagnosing PAD [59,60]. Wall calciﬁcations are common in
subjects with long-lasting diabetes, those undergoing dial-
ysis (particularly if diabetic) and the elderly.One test that is currently used to overcome the problem
of calciﬁcations is to measure toe systolic pressure and
calculate the ratio between it and brachial systolic pres-
sure (the toe/brachial index, TBI) [61]. This is possible
because toe vessels are generally free of calciﬁcations.
Under normal conditions, the pressure of the hallux is
about 30 mm Hg less than that of the ankle, and the TBI is
>0.71. A TBI of <0.71 is indicative of PAD, but absolute
values of >50 mm Hg indicate sufﬁcient perfusion to
guarantee ulcer healing in diabetic patients, whereas
values of <50 mm Hg indicate critical ischaemia and
values of <0.3 insufﬁcient perfusion for healing [62]. This
test is impossible in patients with digital gangrene.
Transcutaneous oximetry (TcPO2) measures the trans-
cutaneous partial pressure of oxygen, and is indicated for
diabetic patients with ulcerative or gangrenous lesions,
claudication or pain at rest insofar as it is a measure of the
presence and severity of PAD and can provide information
concerning the healing potential of a lesion [63]. The
reference value is 50 mm Hg, whereas values of
<30 mm Hg indicate little healing potential. The rela-
tionship between TcPO2 and perfusion is not linear
because values equal to zero do not really indicate the
absence of ﬂow but a state of severe ischaemia in which all
of the available oxygen is consumed by the tissues. There
are a number of conditions under which the test value
should be considered cautiously: for example, the pres-
ence of peripheral oedema or widespread cellulitis that
can inﬂuence the measurements and lead to unreliable
values. TcPO2 is also used to deﬁne amputation levels as
values of >50 mm Hg predict a good likelihood of surgical
wound healing, whereas healing is uncertain at values of
30e50, and improbable at values of <30 [64].
Duplex ultrasonography (echo Doppler) allows the
morphological/functional study of the vascular tree [65].
According to some experts, the information provided by
duplex scans is sufﬁcient to indicate which patients should
undergo revascularisation, but others believe further
diagnostic evaluations such as magnetic resonance (angio-
MR) or computed tomography angiography (angio-CT) are
necessary. It needs to be underlined that the American
College of Cardiology/American Heart Association guide-
lines recommend the use of angio-MR rather than angio-
CT because it allows better deﬁnition and leads to fewer
technique-related risks [66].
Invasive arteriography is never considered a diagnostic
technique per se, but represents the ﬁrst step in endovas-
cular therapy; it can only be proposed for diagnostic pur-
poses in cases in which the other methods have failed to
deﬁne the extent and topography of stenotic/obstructive
arterial disease.
Diagnostic evaluation before revascularisation
The preoperative evaluation of diabetic patients at risk of
limb loss is a much-debated subject because the need to
characterise the arterial bed of patients with advanced
vasculopathy in a detailed manner conﬂicts not only with
the need to be as uninvasive as possible but also with the
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Furthermore, despite the tumultuous progress of vascular
imaging techniques, none can be considered a gold stan-
dard that satisﬁes all diagnostic needs.
The correct evaluation of patients with PAD cannot be
limited to the lower limbs but should also include the
aortic vessels, abdominal aorta and renal arteries because
this would reduce the number of co-morbidities associated
with revascularisation.
The techniques currently used for vascular studies are
duplex ultrasonography, angio-CT and angio-MR.
Duplex ultrasonography is considered to be the most
important and, in many centres, is the only technique used
before revascularisation procedures. One of its main ad-
vantages is that it provides information concerning the
haemodynamics of the obstructive arteriopathy and the
state of run-off [67]. However, it has often been limited by
its operator dependence and the patient’s condition [68],
although these factors certainly have less impact in centres
that carry out a large number of examinations. Neverthe-
less, a complete evaluation including the renal arteries, the
abdominal aorta, the iliac axes, the femoro-popliteal axis
and leg vessels takes a long time.
The use of angio-CT and angio-MR has made it possible
to obtain repeatable and panoramic images that not only
assist the planning of the revascularisation procedure but
also allow the simultaneous evaluation of any other area of
vascular disease in just a few minutes [69]. However, they
have the drawbacks of being expensive and not widely
available. Among other things, angio-MR is playing an
increasingly important role in pre-revascularisation as-
sessments of the vascular tree because the new-generation
coils make it possible to obtain panoramic views from the
intracranial circulation to the plantar arch and avoid the
use of nephrotoxic contrast media. MR is highly sensitive
and speciﬁc in the various vascular districts, and its per-
formance is similar to that of standard angiography at the
level of the iliac aorta, the femoro-popliteal axis and the
renal and carotid arteries. Its main limitations are related
to venous contamination of the foot, the lack of informa-
tion concerning the type of plaque causing the stenosis/
obstruction (calciﬁed, lipid or ﬁbrous), the absence of
signal in the presence of ferromagnetic artefacts (metal
stents and arthroprostheses) and the general contraindi-
cations to MR such as pacemakers, claustrophobia, etc
[70].
Multilayer angio-CT is currently considered the gold
standard in most vascular districts, where its sensitivity
and speciﬁcity are similar to those of arteriography. It
optimally characterises the type of plaque causing the
stenosis/obstruction and therefore makes it possible to
choose the most suitable technique and material for each
individual procedure, and it provides more information
than MR concerning the surrounding parenchyma and the
presence of associated co-morbidities. Furthermore, tech-
nological advances have reduced acquisition times to a
minimum (a few seconds) and reduced the radiation dose
to acceptable levels. The main limitation of angio-CT is the
use of the iodinated contrast media: these may benephrotoxic in this category of patients, especially as it is
followed by endovascular treatment using arteriography,
which uses the same type of contrast [71,72].
 PAD should be suspected and assessed in all diabetic
subjects with foot ulcers.
 ABI and TBI are good screening tests.
 A semiological diagnosis of PAD is not reliable in
diabetics.
 The non-invasive evaluation of PAD requires the inte-
gration of various tests.
 TcPO2 can predict the healing potential of ischaemic or
ulcerative lesions.
 Doppler ultrasonography provides morphological and
functional information with a good degree of sensitivity
and speciﬁcity.
 Angio-MR or angio-CT is used when further diagnostic
details are required.
 Arteriography should never be considered an exclu-
sively diagnostic test.
Medical therapy
There are currently no published data concerning any
medical treatment of PAD other than revascularisation.
However, it is important to correct any modiﬁable risk
factors for cardiovascular disease, especially perioper-
atively and during the follow-up.
Vasodilators
Prostanoid treatment (i.e., the intravenous infusion of a
stable prostacyclin (PGI2) analogue such as iloprost/
Alprostar for 3e4 weeks) is not an alternative to peripheral
revascularisation in diabetic patients with PAD [73]. For
ethical reasons, no randomised clinical trials have been
carried out in order to compare the efﬁcacy of prostanoid
treatment with that of surgery in patients with critical
ischaemia. However, it is important for relieving pain
while awaiting surgical revascularisation, improving post-
revascularisation perfusion and improving the patients’
quality of life [74].
Anti-platelet agents/anticoagulants
In relation to anti-thrombotic/anticoagulant treatment for
the primary and secondary prevention of PAD, we
recommend following the ninth edition (2012) of the
guidelines of the American College of Chest Physicians and
other recent reviews [75e78].
Diabetic patients aged >50 years who are asymptom-
atic for PAD should undergo primary prevention using
long-term daily aspirin monotherapy (75e100 mg), as in
the case of cardiovascular events.
In the case of secondary prevention, various stages need
to be distinguished:
 Symptomatic PAD (intermittent claudication): aspirin
(75e100 mg day1) or clopidogrel (75 mg day1).
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advisable.
 PAD with intermittent claudication and reduced phys-
ical exercise capacity (without lesions): cilostazol
(100e200 mg day1) in addition to aspirin
(75e100 mg day1) or clopidogrel (75 mg day1).
Pentoxifylline, heparinoids and prostanoids are not
advisable.
 Chronic limb ischaemia or symptomatic PAD and crit-
ical ischaemia/pain at rest/ischaemic lesions awaiting
revascularisation: aspirin (75e100 mg day1) or clopi-
dogrel (75 mg day1).
 Before and after percutaneous transluminal angioplasty
(PTA): dual anti-platelet treatment with aspirin
(75e100 mg day1) and clopidogrel (75 mg day1) for
1 month, followed by long-term single anti-platelet
therapy.
 The guidelines of the European Society of Vascular
Surgery state that the use of oral anticoagulants during
the ﬁrst 6 months after surgical revascularisation in-
creases the primary patency of the graft, although it is
not highly recommended. [79]
The role of the more recent anticoagulants has yet to be
evaluated especially in terms of their cost/efﬁcacy ratio
and the risk of bleeding in relation to the obvious advan-
tage of less frequent blood chemistry checks.
 There is no evidence concerning the use of PAD treat-
ments other than revascularisation in diabetic patients.
 It is essential to correct risk factors perioperatively and
during follow-up.
 Vasodilators are not indicated for the treatment of PAD
in diabetic subjects.
 Anti-platelet therapy is always indicated in diabetics
with PAD.Non-revascularisable patients or candidates for primary
amputation
Primary amputation is a demolitive operation that is not
preceded by any attempt at revascularisation, and it is
considered primary therapy only in some cases of DF.
Major amputations (above the ankle) are necessary when
there is a life-threatening infection that cannot be
controlled by antibiotics. In this context, amputation is
indicated on the basis of the patient’s general condition
and the fact that any delay could affect patient survival.
The next aspect to consider is the residual function of
the limb during the post-reparative phase: necrosis
extending to most of the foot will surely prevent func-
tional recovery and therefore it is unnecessary to proceed
to revascularisation.
Some patients have a functional deﬁcit that is inde-
pendent of the foot lesion (sequelae of a stroke, the posi-
tion of the limb in ﬂexion, etc.) and it effectively preventsdeambulation. In such cases, a major amputation does not
alter the patient’s quality of life and may even lead to an
improvement because it allows the prompt resolution of a
major clinical problem such as infection or pain.
The primary aim of an amputation is to heal the leg as
distally as possible. The energy spent on deambulation
increases with level of the amputation. Preservation of the
knee and a signiﬁcant part of the tibia allows the use of a
light prosthesis, as well as the early and independent
deambulation of old or debilitated patients. In brief, the
ideal level of amputation is the most distal level that has a
possibility of healing, which is about 90% in the case of
above-the-knee amputation and 80% if the joint is pre-
served. In clinical practice, healing capacity at a certain
level can be predicted on the basis of TcPO2.
The return to deambulation plays an essential role in
the quality of life, and major advances in the ﬁelds of
prosthetics and rehabilitation now mean that this is a real
possibility in 50% of cases.
 Primary amputation is indicated in the case of life-
threatening infection or extensive necrosis of the foot.Indications for revascularisation
PAD is a risk factor for amputation [51,80] and needs to be
diagnosed early in order to be able to take all of the
therapeutic measures necessary to avoid it as soon as
possible.
In the case of a foot ulcer in a diabetic patient with PAD,
it is ﬁrst necessary to evaluate the usefulness of revascu-
larisation and then choose the method of revascularisation
on the basis of the following clinical criteria: the healing
potential of the ulcer; the local condition of the foot and its
residual function after the healing process; the condition
of the vascular tree; and ﬁnally the general condition of
the patient.
Healing potential refers to the real possibility of healing
on the basis of foot perfusion. Transcutaneous oximetry
and evaluating the pressure of the toe may be helpful
because, in addition to stenoses and obstructions, they can
determine whether distal blood ﬂow is sufﬁcient to guar-
antee tissue healing. According to the Inter-Society
Consensus for the Management of Peripheral Arterial
Disease (TASC II) document [81], foot lesions generally
heal if toe pressure is >50 mm Hg and TcPO2 >50 mm Hg,
whereas healing is a remote possibility if both are <30 mm
Hg. However, it must be pointed out that TASC II does not
speciﬁcally refer to diabetics but also includes the non-
diabetic population.
In a critical review of TcPO2 levels, Faglia considers
values of <34 mm Hg an absolute indication for revascu-
larisation, with an 85% probability of amputation in the
case of no revascularisation; values of 34e40 mm Hg
represent a less impelling indication for revascularisation,
but there is still a considerable probability of amputation
(about 20%). In the case of values of >40 mm Hg, revas-
cularisation can be considered if the tissue loss is signiﬁ-
cant and there is a need to accelerate healing, or in the
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ment is preferred [82].
In any case, once a perfusion deﬁcit has been identiﬁed,
revascularisation should always be considered. [83].
Another possible situation is one in which the limb is
apparently perfused (TcPO2 >40 mm Hg or toe pressure
>50 mm Hg) but, despite optimal local treatment, the
lesion shows no signs of healing. After having excluded
general negative factors such as malnutrition or underly-
ing osteomyelitis, it is necessary to consider the possibility
that the non-invasive evaluations have overestimated pe-
ripheral perfusion and that there may be undetected
ischaemia. In the presence of an ulcer that does not evolve
positively within 4e6 weeks, an ischaemic component
should always be suspected.
The condition of the foot and its potential functional re-
coverymayabove all condition the therapeutic choiceof limb
salvage or primary amputation. Gangrene may be the ﬁrst
sign of PAD in diabetic patients, and this may give rise to a
false conviction that it is too late for revascularisation [84]
and amputation is the only alternative. However, it should
always be remembered that the local clinical picture may
appear to bemore compromised than it actually is because it
maybegreatly affected byan infection that canbe curedwith
appropriate therapy, and so it may be possible to save a limb
that at ﬁrst sight seems deﬁnitely lost.
There are also situations in which the involvement is
such that there is no possibility of saving the foot and
major amputation is unavoidable. However, even in these
cases (as in the case of partial amputation), it is essential to
investigate the vascular tree because correcting underlying
ischaemia may allow a more distal amputation and the
more rapid healing of the amputated stump.
Even if a lesion is so large that limb salvage seems
impossible or so small that it seems hardly worthy of a
thorough diagnosis, the local condition of the foot should
never condition therapeutic choices in absolute terms,
although various studies have shown that a large ulcer is a
risk factor for healing failure and major amputation [3,13].
The apparently obvious observation that a large ulcer
implies an increased risk of major amputation disguises an
extremely important aspect of managing DF: foot lesions
are never large at the beginning but become so because of
inadequate (and therefore ineffective) treatment or, even
worse, the picture has been completely underestimated
and inappropriate treatment has been continued for a long
time. The concept of ‘time is tissue’ also applies to the foot,
and so delayed or inadequate treatment leads to the irre-
versible loss of portions of foot tissue [85]. In particular, it
has been demonstrated that, if a patient with an acutely
phlegmonous foot is immediately referred to a tertiary
centre [49], the outcome in terms of amputation is surely
better than when he or she is ﬁrst referred to a less suit-
able hospital because, in order to be effective, the neces-
sary treatment (adequate surgical debridement and distal
vascularisation) needs to be performed in a timely manner
[86,87].
Another factor capable of signiﬁcantly conditioning the
choice and method of revascularisation is the involvementof the vascular tree. In order to deﬁne the type of inter-
vention, it is important to assess the condition of the
common iliac and femoral arteries, and equally important
to evaluate distal run-off. There is no way that even
optimal revascularisation will last over time without suf-
ﬁcient downstream blood ﬂow: whether endoluminal or
performed by means of bypass surgery, the revascularisa-
tion must allow the restoration of direct ﬂow up to the
dorsalis pedis or plantar arch [88].
One further aspect that needs to be considered is the
patient’s general condition. The most important of the
many factors to consider are life expectancy and the
presence of co-morbidities, particularly heart failure and
CRI. The supporters of bypass peripheral revascularisation
require a minimum life expectancy of 2 years for a surgical
approach, whereas neither technique is considered suit-
able if life expectancy is <6e12 months [89]. It is probably
better not to generalise but to evaluate the situation from
time to time, also considering the improved quality of life
that comes from pain control when the ischaemia is
removed. In terms of co-morbidities, the entire vascular
tree needs to be carefully assessed: half of the patients
with PAD may have concomitant coronary disease, one-
third concomitant carotid disease and about 15e20%
both [90], and this has both diagnostic and therapeutic
implications.
In terms of diagnosis, diabetic patients should never
undergo distal revascularisation without having under-
gone at least a cardiological evaluation (haemodynamic
status and possibly coronary reserve) and an echo Doppler
examination of the upper aortic trunks in the search for a
haemodynamically signiﬁcant plaque in the territory of
the internal carotid artery. It is clear that priority should be
given to the treatment of any coronary instability and/or
signiﬁcant carotid stenosis.
Diabetes and end-stage renal disease are independent
risk factors for PAD. It has been reported that the preva-
lence of PAD among patients with end-stage renal disease
is as high as 77% [91], and renal insufﬁciency is an inde-
pendent predictor of the non-healing of ischaemic and
neuro-ischaemic ulcers and major amputations [92,93].
Between 22% and 44% of dialysed patients undergo
primary amputations because of ischaemic lesions. These
patients are difﬁcult to treat and their high short-term
mortality rate (3e17%) and low long-term survival rate
(45%) can negatively inﬂuence the decision to undertake
revascularisation [94e98].
Dialysed patients treated with bypass surgery generally
experience worse outcomes than those undergoing PTA
[99], as has also been conﬁrmed in a recent Japanese case
series [100].
In relation to the endovascular treatment of diabetic
patients with renal insufﬁciency, Lepantolo [8] says “that
although there is no evidence supporting endovascular
treatment over open by-pass surgery in these high-risk
patients, endoluminal revascularisation seems to be
attractive as a ﬁrst option provided that the area of the
ulcer can be provided with an adequate blood ﬂow.”
Rabellino et al.[101] used the endovascular technique and
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up of 15 months, and Graziani [48] a salvage rate of 80% in
a series of dialysed patients, about half of whom were
diabetics. Finally, in another recent study of diabetics with
PAD and severe foot lesions [13], outcomes were clearly
worse in the patients on dialysis, although a 1-year limb
salvage rate of 57% was reached in a subsequent series of
unselected patients [102].
Although it is a non-modiﬁable risk factor, patient age
also needs to be considered. Adults up to the age of 65e70
years do not give rise to any age-related problems and
treatment decisions can be made more freely when a pa-
tient’s clinical and chronological age coincide, but the
situation is different in the case of elderly patients with
more severe co-morbidities. Studies of bypass surgery and
angioplasty have shown that age is not an impediment to
either, and even the elderly can beneﬁt from revascular-
isation in terms of limb salvage even though it does not
change their ﬁnal life expectancy [103].
In brief, as in the case of non-diabetic patients, the
indication for revascularisation in diabetics depends on
their clinical picture. Revascularisation is indicated in pa-
tients with chronic obstructive arterial disease and:
 disabling claudication and/or pain at rest and
 a trophic lesion and foot TcPO2 of <30 mm Hg or a
trophic lesion that shows no sign of healing after being
adequately treated for 1 month.
The (absolute or relative) exclusion criteria are a life
expectancy of <6 months, psychiatric disorders, untreat-
able antalgic ﬂexion of the leg on the thigh, chronic bed
conﬁnement and the absence of deambulation.
 Once a perfusion deﬁcit has been diagnosed, revascu-
larisation should always be considered.
 The surgical treatment of any coronary and/or carotid
perfusion deﬁcit has priority over peripheral
revascularisation.
 Diabetic patients with end-stage renal disease treated
by dialysis may be candidates for revascularisation if
they have:
 chronic obstructive arterial disease,
 disabling claudication and/or pain at rest,
 a trophic lesion and a TcPO2 of <30 mm Hg and
 an ulcer that shows no sign of healing after being
adequately treated for 1 month.
 Exclusion criteria are:
 a life expectancy of <6 months,
 severe psychiatric disorders,
 absence of deambulation and
 untreatable ﬂexion of the leg.Choice of revascularisation technique
‘Angioplasty ﬁrst’ strategy
Various studies have evaluated the role of PTA in diabetic
patients with critical PAD, especially diseases of the infra-popliteal vessels [2,12,13,15,17,104e113], the overall results
of which are favourable in terms of feasibility, technical
efﬁcacy, the reduced number of complications and limb
salvage rates.
Although long-term patency is better after bypass sur-
gery than after angioplasty, which is burdened by a high
restenosis rate [114e117], angioplasty can also be proposed
for patients who cannot be candidates for a bypass
because of signiﬁcant co-morbidities, a reduced life ex-
pectancy, infection or gangrene in the possible sites of
distal anastomoses, the unavailability of suitable veins or
the absence of an adequate ‘landing zone’ for the distal
part of the bypass [2,13,15,103,111].
Many patients with critical ischaemia are elderly,
affected by multiple co-morbidities and at high operative
risk [30,118]. These are unsuitable for surgical revascular-
isation, but a percutaneous procedure (technically reduced
to the minimum possible invasiveness) can still be
considered in order to improve their quality of life. An-
gioplasty does not require general anaesthesia and can be
carried out with few contraindications in cardio- and
nephropathic subjects at high surgical and anaesthetic risk
[2,15,111]. In complex cases, it can be divided into various
steps in order to reduce stress and the volume of contrast
medium administered, by evaluating the clinical result and
renal function after each step. In this way, more aggressive
revascularisation can be restricted to the patients who
really need it and whose renal function has not worsened.
Angioplasty can be easily repeated in the case of
restenosis or reocclusion or be performed after the failure
of bypass surgery [2,119e121].
The considerable industrial effort that has been made to
create new instruments (very long, low-proﬁle balloons,
drug-eluting balloons, atherotomes, medicated and non-
medicated stents, etc.) means that angioplasty can be
increasingly proposed even in extreme situations and as-
sures the better long-term patency of the treated vessels
[121e126].
When patients can be treated either surgically or percu-
taneously, the fundamental rule of an ‘angioplasty ﬁrst
strategy’ is to respect the so-called surgical ‘landing zones’. It
can generally be said that the failure of angioplasty does not
preclude subsequent bypass surgery [127], but there are re-
ports indicating that a distal bypass procedure is more difﬁ-
cult after the failure of percutaneous revascularisation and
associatedwithmore complications and failures [128,129]. It
is therefore imperative that percutaneous revascularisation
procedures be carried out by experts capable of correctly
identifying and technically respecting the ‘landing zones’
required fora subsequentdistalbypass salvageoperation. It is
also necessary to use stents very carefully because any
restenosis/reocclusion makes subsequent (surgical or
percutaneous) treatment difﬁcult or impossible.
By the same token, the use of open surgery should not
compromise the possibility of future percutaneous treat-
ment: for example, ligation of the superﬁcial femoral ar-
tery makes it impossible to perform a subsequent
percutaneous intervention to restore its patency in the
case of bypass failure.
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there are some forms of vascular obstruction that should
preferentially be treated surgically. Obstructive disease of
the common femoral artery and its bifurcation are gener-
ally not related to diabetic arterial disease [130], and can
be resolved by means of relatively trauma-free surgery
requiring little anaesthesia in almost all cases. Another
example is an extremely long occlusion of the femoro-
popliteal and infra-popliteal axes, although there is no
consensus concerning the length of the obstruction and
local expertise is particularly important: the percutaneous
treatment of such lesions is currently burdened by a high
incidence of restenosis and repeat procedures
[115,130,131], whereas a distal bypass in an autologous
vein is a more effective and longer-lasting solution
[114,115,132].
Surgical revascularisation by means of a bypass should
be performed after having visualised the vascular tree by
means of Doppler ultrasonography, angio-CT, angio-MR or
angiography, and considered a series of important vari-
ables that condition the success of the procedure and its
complications (see ﬂow chart in Fig. 1).
The patient’s general clinical condition: The risks associ-
ated with bypass surgery (the type of bypass and the type
of anaesthesia) should be evaluated in relation to the pa-
tient’s clinical condition (age, co-morbidities and life
expectancy).
Foot lesions: Percutaneous revascularisation can be
proposed for substantially any type of foot lesion, but
bypass surgery requires a careful evaluation of the site of
distal anastomosis, which may be more or less affected by
tissue alterations. Both methods should also be evaluatedFigure 1 Revascularisation strategy in diabetic patients with critical limb
infrapopliteal vessels.on the basis of the type of orthopaedic surgical correction
programmed for the type of lesion: forefoot amputations
can interrupt vascular connections between the dorsal and
plantar systems making their respective vascularisations
functionally ‘terminal’.
The type of ‘bypass’ (prosthesis/vein): It is necessary to
consider the type of bypass (proximal/distal), the avail-
ability of a vein and its quality.
Vessel destined for distal anastomosis: The characteristics
of the vessel used to receive the distal anastomosis of the
bypass should be evaluated: its diameter, the presence of
disease/calciﬁcations, the site of the ischaemic lesion and
the presence of small distal vessel disease causing a poor
distal run-off [133,134]. While bypass surgery can be
applied only when a suitable distal target vessel is recog-
nised at some level in the vascular tree of the leg, angio-
plasty can be extended to the foot vessels, opening and
improving the foot distribution system in the case of very
distal disease [135e137]. The pedaleplantar loop tech-
nique can often restore a direct arterial inﬂow from both
tibial arteries achieving a complete below-the-knee and
below-the-ankle revascularisation and providing a high
rate of acute success, intended as the ability to cross the
lesions and inﬂate the balloon, achieving adequate angio-
graphic results, without periprocedural complications
[138e141]. PTA in diabetic patients with PAD is feasible and tech-
nically efﬁcient, reduces the number of complications
and increases limb salvage rates because it can be
applied in patients unsuitable for bypass surgery.ischaemia due to extensive disease of the femoro-popliteal axis and/or
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morbidities, a reduced life expectancy and signiﬁcant
tissue involvement.
 PTA should be carried out in such a way that it does not
preclude subsequent bypass surgery.
 Classical surgery is indicated in the case of the
involvement of the common femoral artery and its
bifurcation, or extremely long occlusions (as judged by
the surgeon) of the femoro-popliteal and infra-popliteal
arteries.Objectives of revascularisation
Correctly identifying the vascular anatomy of the patient
in relation to his/her tissue lesions is fundamental for
guiding decisions concerning the strategy of
revascularisation.
 Complete revascularisation.
Peregrin analysed the clinical success rates of PTA in
diabetic patients with CLI by considering the number of
successfully treated infra-popliteal vessels [142]. The re-
sults showed that complete revascularisation is better than
partial revascularisation: the 1-year limb salvage rate was
56% without any direct ﬂow to the foot (no open infra-
popliteal vessels) and, respectively, 73%, 80% and 83%
with one, two and three open vessels. Faglia demonstrated
that angioplasty of the tibial arteries led to better results in
terms of limb salvage than the revascularisation of the
peroneal artery alone [143].
 Wound-related artery
When it is not possible to obtain complete revascular-
isation for technical reasons or because of the need to
reduce the duration of the procedure and the dose of
contrast medium, efforts should concentrate on the
wound-related artery, that is, the revascularisation should
aim at reopening the artery irrigating the angiosome of the
foot affected by the ischaemic lesion(s) [144,145]. Revas-
cularisation of the wound-related artery is associated with
higher limb salvage rates than revascularisation of the
arteries running to other angiosomes [146,147]. Even in the
case of surgical revascularisation by means of a bypass,
Neville has shown that a direct bypass on the wound-
related artery leads to higher limb salvage rates [134].
If tibial artery treatment is technically impossible, an-
gioplasty of the distal perforating branches of the peroneal
artery is a successful practicable option.
Neither complete nor wound-related artery revascu-
larisation should be pursued uncritically, but both should
be personalised on the basis of a realistic technical strat-
egy, the type of tissue lesions and their orthopaedic sur-
gical treatment and the patient’s general clinical condition.
[148]
 The main aim of revascularisation is to reopen all
occluded arteries. In the case of technical impossibility, it is better to
target the recanalisation of the wound-related artery in
accordance with the concept of angiosomes.
 Revascularisation should be personalised on the basis of
the overall clinical picture of the foot.Follow-up of revascularised patients
There are currently no unequivocal criteria that deﬁne
with certainty the most appropriate follow-up methods
for patients who have undergone revascularisation
because of ischaemic DF. This is probably due to the het-
erogeneity of patients with CLI: these may be relatively
young with a good life expectancy and be suitable for the
application of severe follow-up criteria that consider
vascular, tissue and general aspects. However, there are
also patients characterised by a ‘terminal’ picture of
widespread atherosclerotic disease, who therefore have a
very limited life expectancy in whom the follow-up should
be less invasive.
Generally, the follow-up should be clinical, oximetric
and/or ultrasonographic, and the examinations should
take place 1, 3, 6 and 12 months after treatment, and every
12 months thereafter. However, just as the treatment of DF
needing a multidisciplinary approach, we believe that the
follow-up of revascularised patients should also be global,
multidisciplinary and personalised, and take into account
the following key elements.Vascular follow-up criteria
The criteria indicating the purely haemodynamic success
of revascularisation are primary and secondary patency,
that is, the capacity of the revascularisation procedure to
guarantee the continued patency of the treated vessel or
bypass [41].
In the case of a bypass, the follow-up should include
Doppler ultrasonography in order to detect any restenosis
(generally of the anastomosis) or the upstream or down-
stream progression of bypass disease; the treatment of
such obstructions is fundamental as it prolongs the life of
the bypass itself [149]. Although randomised trials have
not shown any real beneﬁt of a close follow-up in vein
bypasses [150e152], there is a clear beneﬁt in the pros-
thetic or composite bypasses [153,154]. The recent guide-
lines of the European Society of Vascular Surgery
recommend at least using the ankle brachial index to
select patients who should be sent for a Doppler ultraso-
nography examination [155].
In the case of percutaneous revascularisation, the
follow-up criteria are uncertain. Given that extreme
revascularisation of the infra-popliteal arteries is burdened
by early restenoses (70% after 3 months) [131], an exclu-
sively vascular follow-up aimed at identifying and treating
such restenoses could lead to an incessant re-treatment
without reﬂecting the clinical reality. The occurrence of
restenosis is not always an indication for re-treatment per
se, but re-treatment should be considered in patients with
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process of wound healing has been interrupted.
However, it is important to recognise that in some pa-
tients percutaneous revascularisation enables the
reopening of extended segments of multi-level vessels,
often with extreme difﬁculty. It allows the reconstruction
of a fragile ﬂow line up to the foot, to which the mainte-
nance in time through a close vascular follow-up protocol,
the same way as for distal bypasses, can be deemed
necessary. A focal restenosis can be simply, rapidly and
often lastingly treated, whereas its subsequent evolution
into occlusion (and the consequent extension of the up-
stream and downstream thrombosis of the original lesion)
needs more complex treatment, especially in the case of
intra-stent occlusions, and is burdened by a high rate of
recurrence.
A follow-up based on vascular criteria should therefore
be personalised for each individual patient and based on
the type of revascularisation.
Perfusional follow-up criteria
By ‘perfusional criteria’, we mean TcPO2 measurements
that indicate the real degree of tissue perfusion regardless
of whether it occurs through patent native vessels, revas-
cularised vessels or collateral circulation. Given the rela-
tionship between healing potential and oximetry values,
periodic oximetric evaluations are surely helpful, espe-
cially in patients whose skin lesions show little sign of
healing notwithstanding revascularisation. Oximetry
values of <30 mm Hg are indicative of low tissue perfu-
sion, but it might be useful to repeat the measurement
after a few days before considering the revascularisation a
failure because it has been observed that TcPO2 values
gradually increase 1 month after successful revascularisa-
tion, whereas they remain low in the case of ineffective
revascularisation [156].
Clinical follow-up criteria
These criteria include limb salvage (the avoidance of major
amputation of the leg or thigh), wound healing (the
complete closure of skin lesions) and healing after ‘minor
amputation’ of the toes, rays or tarsal region. Clinical
criteria such as the healing time of foot lesions, the
restoration of walking capacity and the time needed for
this restoration (time to walking) are currently under-
estimated in the literature and should be reconsidered as
primary criteria.
General follow-up criteria
One of the aspects that can never be emphasised enough is
the close relationship between diabetes and cardiovascular
diseases. If this is true for the diabetic population in gen-
eral, it is even truer for those with ongoing vascular
complications. About 50% of diabetic patients with PAD
have an associated coronary disease, 30% have carotid ar-
tery disease and about 15e20% have both simultaneously.Recent data show that patients with PAD treated suc-
cessfully by percutaneous lower extremity revascularisa-
tion have better cardiovascular outcomes than those
treated by conservative medical therapy alone [157]. The
known cardiovascular risk factors, such as hyper-
cholesterolaemia, hypertension and smoking, are made
more aggressive by the presence of diabetes, particularly if
there is no metabolic compensation. Given the pathogenic
role played by risk factors in the manifestation and rapid
evolution of cardiovascular disease, it can be presumed
that they can also signiﬁcantly inﬂuence the results of
revascularisation over time and the reparative response of
tissue lesions.
1. Revascularisation should always be followed by a strict
follow-up.
2. Periodic oximetric evaluations should be performed.
3. Clinical symptoms and ulcer evolution must be
frequently monitored.
4. Cardiovascular risk factors must be corrected.
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